HFA Premium Access

Discontinuation of guideline-recommended heart failure treatments after a first hospitalization for heart failure - An analysis from the SwedeHF registry

Congress Presentation

3 more presentations in this session

Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction: a post hoc analysis of the DAPA-HF trial

Speaker: Doctor J. Butt (Copenhagen, DK)


Distinct pathophysiological pathways in women and men with heart failure

Speaker: Doctor A. Ravera (Brescia, IT)


The effect of dapagliflozin according to iron status and its effect on iron metabolism: insights from DAPA-HF

Speaker: Doctor K. Docherty (Glasgow, GB)


Access the full session

Young Investigator Award: clinical research

Speakers: Doctor J. Butt, Doctor A. Ravera, Doctor K. Docherty

About the event


Heart Failure 2022

21 May - 24 May 2022

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb